nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.03.2018 | Food Allergy (T Green, Section Editor)

Current Status of Potential Therapies for IgE-Mediated Food Allergy

verfasst von: Christopher P. Parrish, Daniel Har, J. Andrew Bird

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies.

Recent Findings

Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT.

Summary

OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergic infants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.

Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9–17. https://doi.org/10.1542/peds.2011-0204.PubMedCrossRef

Nwaru BI, Hickstein L, Panesar SS, Roberts G, Muraro A, Sheikh A, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy. 2014;69(8):992–1007. https://doi.org/10.1111/all.12423.PubMedCrossRef

Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention and management. J Allergy Clin Immunol. 2017; https://doi.org/10.1016/j.jaci.2017.11.003.

Flokstra-de Blok BM, Dubois AE, Vlieg-Boerstra BJ, Oude Elberink JN, Raat H, DunnGalvin A, et al. Health-related quality of life of food allergic patients: comparison with the general population and other diseases. Allergy. 2010;65(2):238–44. https://doi.org/10.1111/j.1398-9995.2009.02121.x.PubMedCrossRef

Mansfield L. Successful oral desensitization for systemic peanut allergy. Ann Allergy Asthma Immunol. 2006;97(2):266–7. https://doi.org/10.1016/S1081-1206(10)60026-9.PubMedCrossRef

Patriarca G, Nucera E, Pollastrini E, De Pasquale T, Lombardo C, Buonomo A, et al. Oral rush desensitization in peanut allergy: a case report. Dig Dis Sci. 2006;51(3):471–3. https://doi.org/10.1007/s10620-006-3157-4.PubMedCrossRef

Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654–60. https://doi.org/10.1016/j.jaci.2010.12.1111.PubMedPubMedCentralCrossRef

Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–75 e6. https://doi.org/10.1016/j.jaci.2013.11.007.PubMedCrossRef

Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82 e1–6. https://doi.org/10.1016/j.jaci.2014.11.005.

10.

Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10. https://doi.org/10.1016/j.jaci.2013.12.1037.PubMedPubMedCentralCrossRef

11.

Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13. https://doi.org/10.1056/NEJMoa1414850.PubMedPubMedCentralCrossRef

12.

• Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–81 e8. https://doi.org/10.1016/j.jaci.2016.05.027. First report suggesting peanut OIT for peanut-allergic children in early childhood (9–36 mos) is safe and may lead to a higher likelihood of inducing SU. PubMedCrossRef

13.

•• Bird JA, Spergel JM, Jones SM, Rachid R, Assa’ad AH, Wang J et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract 2017. https://doi.org/10.1016/j.jaip.2017.09.016 . Multi-center phase 2 trial using a standardized product for OIT showing safe and effective desensitization for peanut-allergic children, adolescents and young adults.

14.

Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, De Pasquale T, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther. 2003;17(3):459–65. https://doi.org/10.1046/j.1365-2036.2003.01468.x.PubMedCrossRef

15.

Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB. Food allergy in children: results of a standardized protocol for oral desensitization. Hepato-Gastroenterology. 1998;45(19):52–8.PubMed

16.

Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy. 2004;59(9):980–7. https://doi.org/10.1111/j.1398-9995.2004.00542.x.PubMedCrossRef

17.

Zapatero L, Alonso E, Fuentes V, Martinez MI. Oral desensitization in children with cow’s milk allergy. J Investig Allergol Clin Immunol. 2008;18(5):389–96.PubMed

18.

Alvaro M, Giner MT, Vazquez M, Lozano J, Dominguez O, Piquer M, et al. Specific oral desensitization in children with IgE-mediated cow’s milk allergy. Evolution in one year. Eur J Pediatr. 2012;171(9):1389–95. https://doi.org/10.1007/s00431-012-1739-z.PubMedCrossRef

19.

Sanchez-Garcia S, Rodriguez del Rio P, Escudero C, Garcia-Fernandez C, Ramirez A, Ibanez MD. Efficacy of oral immunotherapy protocol for specific oral tolerance induction in children with cow’s milk allergy. Isr Med Assoc J. 2012;14(1):43–7.PubMed

20.

Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy. 2007;62(11):1261–9. https://doi.org/10.1111/j.1398-9995.2007.01501.x.PubMedCrossRef

21.

Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2008;122(6):1154–60. https://doi.org/10.1016/j.jaci.2008.09.030.PubMedPubMedCentralCrossRef

22.

Narisety SD, Skripak JM, Steele P, Hamilton RG, Matsui EC, Burks AW, et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow’s milk allergy. J Allergy Clin Immunol. 2009;124(3):610–2. https://doi.org/10.1016/j.jaci.2009.06.025.PubMedPubMedCentralCrossRef

23.

Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55, 55 e1–5. https://doi.org/10.1016/j.jaci.2011.10.023.

24.

Paassilta M, Salmivesi S, Maki T, Helminen M, Korppi M. Children who were treated with oral immunotherapy for cows' milk allergy showed long-term desensitisation seven years later. Acta Paediatr. 2016;105(2):215–9. https://doi.org/10.1111/apa.13251.PubMedCrossRef

25.

Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2013;132(3):737–9 e6. https://doi.org/10.1016/j.jaci.2013.05.006.PubMedPubMedCentralCrossRef

26.

Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M, et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105(5):376–81. https://doi.org/10.1016/j.anai.2010.03.015.PubMedCrossRef

27.

Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199–205. https://doi.org/10.1016/j.jaci.2006.09.016.PubMedCrossRef

28.

Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–43. https://doi.org/10.1056/NEJMoa1200435.PubMedPubMedCentralCrossRef

29.

Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137(4):1117–27 e1–10. https://doi.org/10.1016/j.jaci.2015.12.1316.

30.

Escudero C, Rodriguez Del Rio P, Sanchez-Garcia S, Perez-Rangel I, Perez-Farinos N, Garcia-Fernandez C, et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45(12):1833–43. https://doi.org/10.1111/cea.12604.PubMedCrossRef

31.

Caminiti L, Pajno GB, Crisafulli G, Chiera F, Collura M, Panasci G, et al. Oral immunotherapy for egg allergy: a double-blind placebo-controlled study, with postdesensitization follow-up. J Allergy Clin Immunol Pract. 2015;3(4):532–9. https://doi.org/10.1016/j.jaip.2015.01.017.PubMedCrossRef

32.

Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S, Nowak-Wegrzyn A. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol. 2008;122(5):977–83 e1. https://doi.org/10.1016/j.jaci.2008.09.007.PubMedCrossRef

33.

Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S, Wanich N et al. Tolerance to extensively heated milk in children with cow’s milk allergy. J Allergy Clin Immunol. 2008;122(2):342–7, 7 e1–2. https://doi.org/10.1016/j.jaci.2008.05.043.

34.

Wood RA, Sicherer SH, Vickery BP, Jones SM, Liu AH, Fleischer DM, et al. The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol. 2013;131(3):805–12. https://doi.org/10.1016/j.jaci.2012.10.060.PubMedCrossRef

35.

Sicherer SH, Wood RA, Vickery BP, Jones SM, Liu AH, Fleischer DM, et al. The natural history of egg allergy in an observational cohort. J Allergy Clin Immunol. 2014;133(2):492–9. https://doi.org/10.1016/j.jaci.2013.12.1041.PubMedPubMedCentralCrossRef

36.

Goldberg MR, Nachshon L, Appel MY, Elizur A, Levy MB, Eisenberg E, et al. Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients. J Allergy Clin Immunol. 2015;136(6):1601–6. https://doi.org/10.1016/j.jaci.2015.05.040.PubMedCrossRef

37.

Bravin K, Luyt D. Home-based oral immunotherapy with a baked egg protocol. J Investig Allergol Clin Immunol. 2016;26(1):61–3.PubMed

38.

Giavi S, Vissers YM, Muraro A, Lauener R, Konstantinopoulos AP, Mercenier A, et al. Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. Allergy. 2016;71(11):1575–84. https://doi.org/10.1111/all.12905.PubMedCrossRef

39.

Rodriguez del Rio P, Diaz-Perales A, Sanchez-Garcia S, Escudero C, do Santos P, Catarino M, et al. Oral immunotherapy in children with IgE-mediated wheat allergy: outcome and molecular changes. J Investig Allergol Clin Immunol. 2014;24(4):240–8.PubMed

40.

Sato S, Utsunomiya T, Imai T, Yanagida N, Asaumi T, Ogura K, et al. Wheat oral immunotherapy for wheat-induced anaphylaxis. J Allergy Clin Immunol. 2015;136(4):1131–3 e7. https://doi.org/10.1016/j.jaci.2015.07.019.PubMedCrossRef

41.

Nowak-Wegrzyn A, Wood RA, Nadeau KC, Pongracic JA, Henning A, Beyer K, et al. Randomized placebo-controlled multicenter clinical trial of wheat oral immunotherapy. J Allergy Clin Immunol. 2017;139((2):AB378. https://doi.org/10.1016/j.jaci.2016.12.904.CrossRef

42.

Gupta N, Aron AR. Urges for food and money spill over into motor system excitability before action is taken. Eur J Neurosci. 2011;33(1):183–8. https://doi.org/10.1111/j.1460-9568.2010.07510.x.PubMedCrossRef

43.

Bird JA, Kulis M, Burk CM, Vickery BP, Jones SM, Burks W. Tree nut- and sesame-specific IgE do not decrease from baseline with peanut oral immunotherapy (OIT). Ann Allergy Asthma Immunol. 2012;109(6):470–1. https://doi.org/10.1016/j.anai.2012.09.004.PubMedCrossRef

44.

Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1. https://doi.org/10.1186/1710-1492-10-1.PubMedPubMedCentralCrossRef

45.

Begin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7. https://doi.org/10.1186/1710-1492-10-7.PubMedPubMedCentralCrossRef

46.

Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124(2):286–91, 91 e1–6. https://doi.org/10.1016/j.jaci.2009.03.045.PubMedPubMedCentralCrossRef

47.

Wasserman RL, Factor JM, Baker JW, Mansfield LE, Katz Y, Hague AR, et al. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. J Allergy Clin Immunol Pract. 2014;2(1):91–6. https://doi.org/10.1016/j.jaip.2013.10.001.PubMedCrossRef

48.

Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(2):292–300, e1-97. https://doi.org/10.1016/j.jaci.2009.05.022.PubMedPubMedCentralCrossRef

49.

•• Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol. 2017;139(3):882-8 e5. https://doi.org/10.1016/j.jaci.2016.07.030. Comprehensive retrospective analysis of peanut-allergic children receiving OIT that shows an increased reaction rate while receiving OIT compared to avoidance.

50.

Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009;124(6):1351–2. https://doi.org/10.1016/j.jaci.2009.09.042.PubMedPubMedCentralCrossRef

51.

Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–9. https://doi.org/10.1016/j.anai.2014.08.004.PubMedCrossRef

52.

Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445–55. https://doi.org/10.1056/NEJMoa052916.PubMedCrossRef

53.

Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505. https://doi.org/10.1034/j.1398-9995.2001.056006498.x.PubMedCrossRef

54.

Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004;113(6):1144–51. https://doi.org/10.1016/j.jaci.2004.03.003.PubMedCrossRef

55.

Lombardi V, Van Overtvelt L, Horiot S, Moussu H, Chabre H, Louise A, et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy. 2008;38(11):1819–29. https://doi.org/10.1111/j.1365-2222.2008.03056.x.PubMed

56.

Mascarell L, Van Overtvelt L, Lombardi V, Razafindratsita A, Moussu H, Horiot S, et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine. 2007;26(1):108–18. https://doi.org/10.1016/j.vaccine.2007.10.050.PubMedCrossRef

57.

Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000;30(12):1804–8. https://doi.org/10.1046/j.1365-2222.2000.00948.x.PubMedCrossRef

58.

Miettinen M, Matikainen S, Vuopio-Varkila J, Pirhonen J, Varkila K, Kurimoto M, et al. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun. 1998;66(12):6058–62.PubMedPubMedCentral

59.

Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow’s milk allergy. J Allergy Clin Immunol. 2004;114(1):131–6. https://doi.org/10.1016/j.jaci.2004.03.036.PubMedCrossRef

60.

Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002;109(1):119–21. https://doi.org/10.1067/mai.2002.120273.PubMedCrossRef

61.

Rautava S, Arvilommi H, Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res. 2006;60(2):221–4. https://doi.org/10.1203/01.pdr.0000228317.72933.db.PubMedCrossRef

62.

Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–44 e8. https://doi.org/10.1016/j.jaci.2014.11.034.PubMedCrossRef

63.

Hsiao K-C, Ponsonby A-L, Axelrad C, Pitkin S, Tang MLK, Burks W, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child Adolescent Health. 2017;1(2):97–105. https://doi.org/10.1016/s2352-4642(17)30041-x.CrossRef

64.

Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, team Ps. The longitudinal impact of probiotic and peanut oral immunotherapy (PPOIT) on health related quality of life (HRQL). Allergy 2017. https://doi.org/10.1111/all.13330.

65.

Shaker MS. An economic analysis of a peanut oral immunotherapy study in children. J Allergy Clin Immunol Pract. 2017;5(6):1707–16. https://doi.org/10.1016/j.jaip.2017.04.016.PubMedCrossRef

66.

Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130(5):1123–9 e2. https://doi.org/10.1016/j.jaci.2012.05.039.PubMedPubMedCentralCrossRef

67.

Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309–10 e1. https://doi.org/10.1016/j.jaci.2011.01.051.PubMedCrossRef

68.

Leung DY, Sampson HA, Yunginger JW, Burks AW, Jr., Schneider LC, Wortel CH et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348(11):986–993. https://doi.org/10.1056/NEJMoa022613.

69.

Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622–4. https://doi.org/10.1016/j.jaci.2011.04.009.PubMedPubMedCentralCrossRef

70.

Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–74. https://doi.org/10.1016/j.jaci.2013.09.046.PubMedPubMedCentralCrossRef

71.

Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–10 e1–11. https://doi.org/10.1016/j.jaci.2015.10.005.

72.

MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2016; https://doi.org/10.1016/j.jaci.2016.08.010.

73.

Lafuente I, Mazon A, Nieto M, Uixera S, Pina R, Nieto A. Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg. Pediatr Allergy Immunol. 2014;25(7):717–9. https://doi.org/10.1111/pai.12259.PubMedCrossRef

74.

Srivastava KD, Siefert A, Fahmy TM, Caplan MJ, Li XM, Sampson HA. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. J Allergy Clin Immunol. 2016;138(2):536–43 e4. https://doi.org/10.1016/j.jaci.2016.01.047.PubMedCrossRef

75.

Bannon GA, Cockrell G, Connaughton C, West CM, Helm R, Stanley JS, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol. 2001;124(1–3):70–2. 53672. https://doi.org/10.1159/000053672.PubMedCrossRef

76.

Srivastava KDLX, King N, Stanley S, Bannon GA, Burks W, Sampson HA. Immunotherapy with modified peanut allergens in a murine model of peanut allergy. J Allergy Clin Immunol. 2002;109(1):S287. https://doi.org/10.1016/S0091-6749(02)82012-7.CrossRef

77.

Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013;68(6):803–8. https://doi.org/10.1111/all.12158.PubMedPubMedCentralCrossRef

78.

Swoboda I, Bugajska-Schretter A, Linhart B, Verdino P, Keller W, Schulmeister U, et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol. 2007;178(10):6290–6. https://doi.org/10.4049/jimmunol.178.10.6290.PubMedCrossRef

79.

Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Dupont C, et al. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice. Clin Exp Allergy. 2014;44(6):867–81. https://doi.org/10.1111/cea.12312.PubMedPubMedCentralCrossRef

80.

Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139(1):189–201.e4. https://doi.org/10.1016/j.jaci.2016.03.057.PubMedCrossRef

81.

Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Benhamou PH, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 2011;186(10):5629–37. https://doi.org/10.4049/jimmunol.1003134.PubMedCrossRef

82.

Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40(4):659–67. https://doi.org/10.1111/j.1365-2222.2009.03430.x. PubMedCrossRef

83.

Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH. Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125(5):1165–7. https://doi.org/10.1016/j.jaci.2010.02.029.PubMedCrossRef

84.

Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016;137(4):1258–61 e10. https://doi.org/10.1016/j.jaci.2016.01.008.PubMedCrossRef

85.

Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–52 e9. https://doi.org/10.1016/j.jaci.2016.08.017.PubMedCrossRef

86.

•• Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–809. https://doi.org/10.1001/jama.2017.16591. Phase 2 clinical trial reporting the safety of EPIT for treatment of peanut allergy and suggesting an increased reactivity threshold after 1 year of treatment for children 4 to 11 years old. PubMedCrossRef

87.

Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep. 2014;14(11):473. https://doi.org/10.1007/s11882-014-0473-1. PubMedCrossRef

88.

Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073–9. https://doi.org/10.1016/j.jaci.2005.08.027.PubMedCrossRef

89.

Enrique E, Malek T, Pineda F, Palacios R, Bartra J, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol. 2008;100(3):283–4. https://doi.org/10.1016/s1081-1206(10)60456-5.PubMedCrossRef

90.

de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy. 2006;61(10):1238–9. https://doi.org/10.1111/j.1398-9995.2006.01196.x.PubMedCrossRef

91.

Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE, Gonzalez-Mancebo E, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009;64(6):876–83. https://doi.org/10.1111/j.1398-9995.2008.01921.x.PubMedCrossRef

92.

Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640–6.e1. https://doi.org/10.1016/j.jaci.2010.12.1083.

93.

Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–27.e1–7. https://doi.org/10.1016/j.jaci.2012.11.011.

94.

Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;135(5):1240–8.e1–3. https://doi.org/10.1016/j.jaci.2014.12.1917.

95.

Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82.e1–6. https://doi.org/10.1016/j.jaci.2014.11.005.

96.

Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55, 55.e1–5. https://doi.org/10.1016/j.jaci.2011.10.023.

Titel: Current Status of Potential Therapies for IgE-Mediated Food Allergy
verfasst von: Christopher P. Parrish
Daniel Har
J. Andrew Bird
Publikationsdatum: 01.03.2018
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 3/2018
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-018-0772-z

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Current Status of Potential Therapies for IgE-Mediated Food Allergy

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Impact of Particulate Air Pollution on Cardiovascular Health

Diagnostic Tools for Inborn Errors of Human Immunity (Primary Immunodeficiencies and Immune Dysregulatory Diseases)

Do Glutathione S-Transferase Genes Modify the Link between Indoor Air Pollution and Asthma, Allergies, and Lung Function? A Systematic Review

Granulomatous-Lymphocytic Interstitial Lung Disease in 22q11.2 Deletion Syndrome: a Case Report and Literature Review

The Effect of Inhalant Organic Dust on Bone Health

Indoor Environmental Interventions and their Effect on Asthma Outcomes

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO